Drug class in one race
RET drugs for Non-Small Cell Lung Cancer
6 tracked RET drugs in the Non-Small Cell Lung Cancer race. The class explanation lives on the RET page; the full indication pipeline across every mechanism is on the Non-Small Cell Lung Cancer page.
2 approved / phase 42 Phase 1/22 preclinical / unstaged
Head-to-head evidence: EP0031 vs Pralsetinib · HEC169096 vs Pralsetinib · KL590586 vs Pralsetinib · Pralsetinib vs Selpercatinib · Pralsetinib vs TAS0953